NEW
YORK, April 16, 2024 /PRNewswire/ --
Prolerity Clinical Research ("Prolerity), a clinical
research site network and an AHP portfolio company,
announced today that it has appointed Drew
Domescik as Chief Financial Officer. Prolerity currently
owns and operates 11 research sites across Louisiana, Florida, New
Jersey, and New York.
"I could not be more excited to have Drew join me in pursing the
promise of building Prolerity into a leading national site
management network," said Jeff
Williams, CEO of Prolerity. Prolerity is a research site
network with therapeutic coverage across complex and challenging
phase I-III trials, including gastroenterology, cardiology, CNS and
metabolic disease. "Given Drew's deep industry experience in site
networks and clinical research, as well as his finance and
transactional background, he will be central to our focus on
driving operational efficiency while we continue to make
transformative investments," Jeff added.
"I am truly excited about the opportunity to work with Jeff and
AHP to build a mission driven company focused on meeting the needs
patients and drug developers," said Drew
Domescik. "I feel fortunate that Prolerity has such
extremely high quality sites, talented investigators and staff."
Previously, Drew was the CFO at Javara Inc., an integrated research
organization. Prior to Javara, Drew held corporate development and
finance roles at PPD, Validant and in investment banking.
Prolerity owns New Orleans based Tandem Clinical Research
("Tandem") which has become known for operating best-in-class
research sites for NASH/NAFLD and neurodegenerative studies by
demonstrating excellence in study feasibility, contracting, patient
recruitment, patient retention, and quality. Tandem recently
expanded into its newly developed, purpose-built 12,000 sq ft
headquarters in Marrero, LA and a
new 13,000 sq ft space in Maitland,
FL through its ClinCloud division.
About Prolerity:
Prolerity Clinical Research strives to advance the science of
medicine while improving the quality of life for patients through
clinical research. Prolerity's professional medical team is
committed to serving diversified populations while ensuring our
drug development customers can achieve their study objectives
across our growing network of sites in Louisiana, Florida, New
York, and New Jersey.
About AHP:
AHP is a New York based
investment management firm focused exclusively on the healthcare
industry. AHP seeks to deploy a high touch, value-add approach to
investing in healthcare companies at the intersections of change.
AHP's mission is to create shared value by partnering with
companies that enable cost-effective, quality enhancing services to
the healthcare system. For more information, please
visit AHPartners.com.
View original
content:https://www.prnewswire.com/news-releases/ahp-backed-prolerity-clinical-research-appoints-drew-domescik-as-cfo-302118003.html
SOURCE Assured Healthcare Partners LLC